Prostate cancer cells have been hypothesized to progress to castration resistance through a multitude of androgen receptor (AR) modifications including amplification, gene rearrangements or mutations, altered expression of transcriptional co-regulators and de novo steroidogenesis [1–6]. This evidence concerns the gene AR and prostate carcinoma.